AIA Group Ltd Acquires New Stake in DexCom, Inc. $DXCM

AIA Group Ltd acquired a new stake in DexCom, Inc. (NASDAQ:DXCM) during the 1st quarter, Holdings Channel reports. The institutional investor acquired 78,000 shares of the medical device company’s stock, valued at approximately $4,898,000.

Other hedge funds also recently made changes to their positions in the company. Reflection Asset Management purchased a new stake in shares of DexCom in the fourth quarter valued at about $25,000. Ascentis Independent Advisors purchased a new position in DexCom during the first quarter worth about $25,000. CVA Family Office LLC raised its holdings in DexCom by 48.5% during the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after purchasing an additional 147 shares in the last quarter. MCF Advisors LLC acquired a new stake in DexCom in the fourth quarter valued at about $32,000. Finally, ORG Partners LLC lifted its position in DexCom by 124.3% in the fourth quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 281 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Piper Sandler reissued an “overweight” rating and set a $88.00 target price (up from $75.00) on shares of DexCom in a research note on Monday, June 15th. Truist Financial lifted their price target on DexCom from $80.00 to $87.00 and gave the company a “buy” rating in a research note on Thursday. Bank of America dropped their price objective on DexCom from $100.00 to $80.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Raymond James Financial reiterated a “strong-buy” rating and issued a $91.00 price objective on shares of DexCom in a research report on Monday, June 8th. Finally, William Blair raised DexCom to a “strong-buy” rating in a report on Friday, May 15th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, DexCom currently has an average rating of “Moderate Buy” and an average target price of $85.36.

Insider Activity at DexCom

In other news, EVP Jon Coleman sold 4,912 shares of the business’s stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $73.00, for a total value of $358,576.00. Following the completion of the transaction, the executive vice president directly owned 100,361 shares of the company’s stock, valued at $7,326,353. The trade was a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 4,000 shares of the company’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $74.13, for a total value of $296,520.00. Following the completion of the sale, the director owned 52,852 shares in the company, valued at $3,917,918.76. This represents a 7.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 71,750 shares of company stock valued at $5,163,241 in the last ninety days. 0.28% of the stock is owned by insiders.

DexCom Price Performance

DXCM stock opened at $76.65 on Monday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64. The company’s 50 day simple moving average is $71.16 and its 200-day simple moving average is $68.74. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $89.98. The firm has a market capitalization of $29.58 billion, a PE ratio of 32.76, a P/E/G ratio of 1.26 and a beta of 1.45.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The firm had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. During the same quarter in the prior year, the company earned $0.32 EPS. DexCom’s revenue was up 15.0% on a year-over-year basis. Equities analysts expect that DexCom, Inc. will post 2.57 earnings per share for the current fiscal year.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.